ArticleJournal of endocrinological investigation2005
Long-term potassium citrate therapy and bone mineral density in idiopathic calcium stone formers.
Article in Journal of endocrinological investigation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Trial
- Dietary acid load is associated with lower bone mineral density in men with low intake of dietary calcium.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2014Trial
- Bone mineral density assessment in patients with cystinuria.Journal of nephrology · 2025Article
- Enhancing Stability of High-Concentration β-Tricalcium Phosphate Suspension for Biomedical Application.Materials (Basel, Switzerland) · 2022Article
- UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Should pediatric idiopathic hypercalciuria be treated with hypocalciuric agents?World journal of nephrology · 2021Article
- Chlorthalidone with potassium citrate decreases calcium oxalate stones and increases bone quality in genetic hypercalciuric stone-forming rats.Kidney international · 2021Article
- Osteoporosis is a Predictive Factor for Nephrolithiasis in an Adult Free-Living Caucasian Population From Southern Italy: A Longitudinal Retrospective Study Based on a General Practice Database.Calcified tissue international · 2020Article
- Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats.Journal of the American Society of Nephrology : JASN · 2019Article
- Citrate chemistry and biology for biomaterials design.Biomaterials · 2018Review
- Article
- The relation between bone and stone formation.Calcified tissue international · 2013Article
- Idiopathic hypercalciuria and bone health.Current osteoporosis reports · 2012Review
- Longitudinal study of bone mineral density in children with idiopathic hypercalciuria.Pediatric nephrology (Berlin, Germany) · 2012Article
- Nephrolithiasis-associated bone disease: pathogenesis and treatment options.Kidney international · 2011Review
- Bone disease in medullary sponge kidney and effect of potassium citrate treatment.Clinical journal of the American Society of Nephrology : CJASN · 2009Article
- Article
- Independent and combined effect of nutrition and exercise on bone mass development.Journal of bone and mineral metabolism · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several authors have described an association between idiopathic calcium (Ca) stone disease and bone mass reduction. Hypocitraturia is a frequent feature of urolithiasis, and alkaline citrate has been recommended as one of the choice treatments in this disease. Some evidence exists as to the positive effect of potassium (K) citrate therapy on bone mass. The aim of this work was the longitudinal evaluation of bone mineral density (BMD) changes in a group of Ca oxalate stone formers treated with K citrate for two years. Enrolled patients were 120; 109 subjects completed the study (51 males and 58 females). A metabolic study and distal radius BMD measurements were conducted both at baseline (BAS) and at the end of the study (END). BMD (0.451 +/- 0.081 vs 0.490 +/- 0.080 g/cm2), T-score (-1.43 +/- 1.02 vs -0.90 +/- 1.04), net gastrointestinal alkali absorption (40.37 +/- 50.57 vs 61.26 +/- 42.26 mEq/day), urinary citrate (2.53 +/- 1.15 vs 3.10 +/- 1.44 mmol/day) and K (58.93 +/- 22.28 vs 65.45 +/- 23.97 mmol/day) excretion significantly increased from BAS to END. Urinary Ca excretion remained unchanged from BAS to END (5.16 +/- 2.74 vs 5.57 +/- 2.85 mmol/ day). Our results indicate that long-term treatment with K citrate increases forearm BMD in idiopathic Ca stone formers. It seems probable that the alkali load provided by this drug reduces bone resorption by a buffering of the endogenous acid production. K citrate appears to be a further therapeutic opportunity for the management of osteoporosis in Ca stone formers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.